Serum protein signatures as a non-invasive tool for monitoring nonalcoholic steatohepatitis

image of the white paper

NASH and NAFLD are characterized by distinct sets of protein signatures. In our latest white paper, we discuss how researchers have used the SomaScan® Assay to characterize and predict NASH non-invasively, even beating the best available clinical model. Download the white paper to learn more about how to get the most out of your NASH and NAFLD clinical samples with the world’s most impactful protein assay.


More White Papers

White paperThe SomaScan® Assay enables discovery of blood-based biomarkers in neurodegenerative diseases

Learn more

White paperCOVID-19 and the SomaScan® Platform

Learn more

White paperAssessing pre-analytical variation for more accurate proteomic data

Learn more

Explore external publications in our interactive viewer